{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T10:49:27Z","timestamp":1776077367568,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.clinthera.2017.03.005","type":"journal-article","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T21:00:16Z","timestamp":1490734816000},"page":"849-862.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons"],"prefix":"10.1016","volume":"39","author":[{"given":"Douglas","family":"Wolf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Skup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna P.","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Kageleiry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingdong","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.03.005_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/0192623311428481","article-title":"Cellular and molecular mechanisms of autoimmune disease","volume":"40","author":"Bolon","year":"2012","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.clinthera.2017.03.005_bib2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MAJ.0b013e31820f8c99","article-title":"Epidemiology of spondyloarthritis in North America","volume":"341","author":"Reveille","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.clinthera.2017.03.005_bib3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10620-012-2371-5","article-title":"Recent trends in the prevalence of Crohn\u05f3s disease and ulcerative colitis in a commercially insured US population","volume":"58","author":"Kappelman","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2017.03.005_bib4","first-page":"S295","article-title":"Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis","volume":"18","author":"Gibofsky","year":"2012","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2017.03.005_bib5","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","article-title":"Psoriasis prevalence among adults in the United States","volume":"70","author":"Rachakonda","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2017.03.005_bib6","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1185\/03007995.2014.969368","article-title":"Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database","volume":"30","author":"Wendling","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2017.03.005_bib7","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.clinthera.2013.07.328","article-title":"Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study","volume":"35","author":"Zhu","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.03.005_bib8","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1185\/03007990903185557","article-title":"Economic burden of psoriasis compared to the general population and stratified by disease severity","volume":"25","author":"Yu","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2017.03.005_bib9","unstructured":"American Autoimmune Related Diseases and National Coalition of Autoimmune Patient Groups. The Cost Burden of Autoimmune Diseases. 2011; http:\/\/www.diabetesed.net\/page\/_files\/autoimmune-diseases.pdf. Accessed July 25, 2016."},{"key":"10.1016\/j.clinthera.2017.03.005_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4103\/0019-5154.53175","article-title":"Biologics: target-specific treatment of systemic and cutaneous autoimmune diseases","volume":"54","author":"Raychaudhuri","year":"2009","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.clinthera.2017.03.005_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000289195","article-title":"Cellular mechanisms of TNF function in models of inflammation and autoimmunity","volume":"11","author":"Apostolaki","year":"2010","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.clinthera.2017.03.005_bib12","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.2174\/156802606778194217","article-title":"Anti-TNF-alpha antibody therapies in autoimmune diseases","volume":"6","author":"Chatzantoni","year":"2006","journal-title":"Curr Top Med Chem"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2017.03.005_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/03946320140270S103","article-title":"Adalimumab in the treatment of immune-mediated diseases","volume":"27","author":"Lapadula","year":"2014","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.clinthera.2017.03.005_bib14","unstructured":"AbbVie. Humira (adalimumab) [prescribing information]. 2002. http:\/\/www.rxabbvie.com\/pdf\/humira.pdf. Accessed July 25, 2016."},{"key":"10.1016\/j.clinthera.2017.03.005_bib15","unstructured":"Janssen. Remicade (infliximab) [prescribing information]. 1998. https:\/\/www.remicade.com\/shared\/product\/remicade\/prescribing-information.pdf. Accessed July 25, 2016."},{"key":"10.1016\/j.clinthera.2017.03.005_bib16","unstructured":"Amgen. Enbrel (etanercept) [prescribing information]. 1998. http:\/\/pi.amgen.com\/united_states\/enbrel\/derm\/enbrel_pi.pdf. Accessed July 25, 2016."},{"key":"10.1016\/j.clinthera.2017.03.005_bib17","unstructured":"UCB. Cimzia (certolizumab pegol) [prescribing information]. 2008. http:\/\/www.ucb-usa.com\/_up\/ucb_usa_com\/documents\/Prescribing_Information.pdf. Accessed July 25, 2016."},{"key":"10.1016\/j.clinthera.2017.03.005_bib18","unstructured":"Janssen. Simponi (golimumab) [prescribing information]. 2009. http:\/\/www.simponi.com\/shared\/product\/simponi\/prescribing-information.pdf. Accessed July 25, 2016."},{"key":"10.1016\/j.clinthera.2017.03.005_bib19","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/rheumatology\/keq169","article-title":"The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis","volume":"49","author":"Lloyd","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2017.03.005_bib20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjd.13437","article-title":"Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response","volume":"172","author":"Signorovitch","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2017.03.005_bib21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/apt.12644","article-title":"Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2017.03.005_bib22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after anti-tnf discontinuation in inflammatory bowel disease: systematic review and meta-analysis","volume":"111","author":"Gisbert","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2017.03.005_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2016.05.044","article-title":"Discontinuation of infliximab in patients with ulcerative colitis is associated with increased risk of relapse: a multinational retrospective cohort study","author":"Fiorino","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2017.03.005_bib24","first-page":"e131","article-title":"Comparison of tiered formularies and reference pricing policies: a systematic review","volume":"3","author":"Morgan","year":"2009","journal-title":"Open Med"},{"key":"10.1016\/j.clinthera.2017.03.005_bib25","unstructured":"US Food and Drug Administration. Biosimilars. http:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/Biosimilars\/, 2015. Accessed July 20, 2016."},{"key":"10.1016\/j.clinthera.2017.03.005_bib26","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3111\/13696998.2010.488985","article-title":"Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons","volume":"13","author":"Wu","year":"2010","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2017.03.005_bib27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1185\/03007991003613910","article-title":"Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension","volume":"26","author":"Signorovitch","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2017.03.005_bib28","unstructured":"Liu YS, Skup M, Lin J, Chao J. Impact of non-medical switching on healthcare costs: a claims database analysis. http:\/\/wwwispororg\/ScientificPresentationsDatabase\/Presentation\/53795. Accessed September 17, 2015."},{"key":"10.1016\/j.clinthera.2017.03.005_bib29","doi-asserted-by":"crossref","unstructured":"Rubin DS, Skup M, Johnson S, Chao J, Gibofsky A. Analysis of outcomes after non-medical switching of anti-tumor necrosis factor agents. Presented at the 10th Congress of the European Crohn\u05f3s and Colitis Organization (ECCO), Barcelona, Spain, February 18-21, 2015.","DOI":"10.1016\/S0016-5085(15)32893-6"},{"issue":"Suppl","key":"10.1016\/j.clinthera.2017.03.005_bib30","first-page":"SP23","article-title":"Impact of therapeutic switching in long-term care","volume":"14","author":"Cote","year":"2008","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2017.03.005_bib31","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4158\/EP11217.OR","article-title":"Consequences of brand switches during the course of pediatric growth hormone treatment","volume":"18","author":"Grimberg","year":"2012","journal-title":"Endocr Pract"},{"key":"10.1016\/j.clinthera.2017.03.005_bib32","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1185\/03007995.2013.871243","article-title":"Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review","volume":"30","author":"Wong","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2017.03.005_bib33","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1185\/03007995.2010.500883","article-title":"Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement","volume":"26","author":"Chang","year":"2010","journal-title":"Curr Med Res Opin"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817301790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817301790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T01:00:15Z","timestamp":1535936415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817301790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0149291817301790"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.03.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}